High Grade B-Cell Lymphoma clinical trials in New York
19 active High Grade B-Cell Lymphoma trials with a site in New York. Describe your situation to see which ones look like a fit.
- A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- DALY II USA/ MB-CART2019.1 for DLBCL
- A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
- TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
- Study of CAR-T Therapy in Older Patients
- Bispecific CD19/CD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies
- P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.